What is the difference between Sotorasib and Adagrasib?

Sotorasib) and adagrasib (Adagrasib) are two targeted drugs used to treat KRAS G12C mutations, mainly used to treat KRAS G12Cmutated non-small cell lung cancer (NSCLC) and other malignant tumors. Although both drugs target the same mutation site, they have some differences in drug structure, clinical application, and efficacy.

Sotoracib and adagrasib are both KRAS G12C mutation inhibitors with similar mechanisms of action. KRAS G12C mutation will lead to the continuous activation of KRAS protein and promote the growth and spread of cancer cells. The two drugs inhibit the growth and proliferation of cancer cells by binding to the mutated ATP binding site of KRAS G12C and inhibiting its activity. However, despite their similar targeting mechanisms, adagrasiib and sotorasiib differ in their chemical structures, which differentiates their pharmacokinetic properties.

In clinical trials, both sotoraxib and adagrasiib demonstrated efficacy against KRAS G12C mutant non-small cell lung cancer. Sotorasiib has demonstrated in multiple clinical trials that it can significantly improve progression-free survival (PFS) and overall survival (OS) in patients, especially in patients with KRAS G12C mutation-positive patients. Although adagrasiib has also shown good efficacy and has a higher disease control rate in some studies, its data are still at an earlier stage than sotoracib, and its advantages in a wide range of people have not yet been fully proven.

The side effects of the two drugs are generally similar, with common side effects including fatigue, nausea, decreased appetite and abnormal liver function. Specifically, sotorasiib may cause mild liver damage in some patients, while adagrasiib's side effects are more related to gastrointestinal symptoms (eg, diarrhea, constipation). Overall, the two drugs are well tolerated, but for patients with hepatic insufficiency, caution is needed when using these drugs and liver function monitoring must be carried out regularly.

Reference materials:https://www.lumakras.com/